Identification of a novel HA conformational change inhibitor of human influenza virus
Identifieur interne : 000249 ( Istex/Corpus ); précédent : 000248; suivant : 000250Identification of a novel HA conformational change inhibitor of human influenza virus
Auteurs : J. Yoshimoto ; M. Kakui ; H. Iwasaki ; T. Fujiwara ; H. Sugimoto ; N. HattoriSource :
- Archives of Virology [ 0304-8608 ] ; 1999-05-01.
Abstract
Summary: Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. The susceptibility of the reassortant viruses between H1 and H3 subtype influenza A viruses to Stachyflin indicated that its target was virus-encoded hemagglutinin (HA). The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. More directly, Stachyflin interfered with HA conformational change induced by low pH or heat treatment. The effect of Stachyflin could not be eliminated by washing of the Stachyflin-treated virus, which caused very specific virucidal effect. This is a remarkable property among small molecules which inhibit low-pH induced HA conformational change. From these findings, we concluded that the mechanism of Stachyflin action is to inhibit HA conformational change which is necessary for virus-cell membrane fusion. Stachyflin may be used as a tool for a study of molecular mechanism of low-pH induced HA conformational change, and offers potential as a pharmaceutical agent.
Url:
DOI: 10.1007/s007050050552
Links to Exploration step
ISTEX:23B352D5518AF38A2976BC28D266B92B7C42B326Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of a novel HA conformational change inhibitor of human influenza virus</title><author><name sortKey="Yoshimoto, J" sort="Yoshimoto, J" uniqKey="Yoshimoto J" first="J." last="Yoshimoto">J. Yoshimoto</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kakui, M" sort="Kakui, M" uniqKey="Kakui M" first="M." last="Kakui">M. Kakui</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Iwasaki, H" sort="Iwasaki, H" uniqKey="Iwasaki H" first="H." last="Iwasaki">H. Iwasaki</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Fujiwara, T" sort="Fujiwara, T" uniqKey="Fujiwara T" first="T." last="Fujiwara">T. Fujiwara</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Sugimoto, H" sort="Sugimoto, H" uniqKey="Sugimoto H" first="H." last="Sugimoto">H. Sugimoto</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hattori, N" sort="Hattori, N" uniqKey="Hattori N" first="N." last="Hattori">N. Hattori</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:23B352D5518AF38A2976BC28D266B92B7C42B326</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1007/s007050050552</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-JW8BS4G7-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000249</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000249</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Identification of a novel HA conformational change inhibitor of human influenza virus</title><author><name sortKey="Yoshimoto, J" sort="Yoshimoto, J" uniqKey="Yoshimoto J" first="J." last="Yoshimoto">J. Yoshimoto</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kakui, M" sort="Kakui, M" uniqKey="Kakui M" first="M." last="Kakui">M. Kakui</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Iwasaki, H" sort="Iwasaki, H" uniqKey="Iwasaki H" first="H." last="Iwasaki">H. Iwasaki</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Fujiwara, T" sort="Fujiwara, T" uniqKey="Fujiwara T" first="T." last="Fujiwara">T. Fujiwara</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Sugimoto, H" sort="Sugimoto, H" uniqKey="Sugimoto H" first="H." last="Sugimoto">H. Sugimoto</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hattori, N" sort="Hattori, N" uniqKey="Hattori N" first="N." last="Hattori">N. Hattori</name><affiliation><mods:affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Archives of Virology</title><title level="j" type="abbrev">Arch. Virol.</title><idno type="ISSN">0304-8608</idno><idno type="eISSN">1432-8798</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1999-05-01">1999-05-01</date><biblScope unit="volume">144</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="865">865</biblScope><biblScope unit="page" to="878">878</biblScope></imprint><idno type="ISSN">0304-8608</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0304-8608</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. The susceptibility of the reassortant viruses between H1 and H3 subtype influenza A viruses to Stachyflin indicated that its target was virus-encoded hemagglutinin (HA). The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. More directly, Stachyflin interfered with HA conformational change induced by low pH or heat treatment. The effect of Stachyflin could not be eliminated by washing of the Stachyflin-treated virus, which caused very specific virucidal effect. This is a remarkable property among small molecules which inhibit low-pH induced HA conformational change. From these findings, we concluded that the mechanism of Stachyflin action is to inhibit HA conformational change which is necessary for virus-cell membrane fusion. Stachyflin may be used as a tool for a study of molecular mechanism of low-pH induced HA conformational change, and offers potential as a pharmaceutical agent.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>J. Yoshimoto</name><affiliations><json:string>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</json:string></affiliations></json:item><json:item><name>M. Kakui</name><affiliations><json:string>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</json:string></affiliations></json:item><json:item><name>H. Iwasaki</name><affiliations><json:string>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</json:string></affiliations></json:item><json:item><name>T. Fujiwara</name><affiliations><json:string>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</json:string></affiliations></json:item><json:item><name>H. Sugimoto</name><affiliations><json:string>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</json:string></affiliations></json:item><json:item><name>N. Hattori</name><affiliations><json:string>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</json:string></affiliations></json:item></author><articleId><json:string>91440865</json:string><json:string>Art2</json:string></articleId><arkIstex>ark:/67375/VQC-JW8BS4G7-Q</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Summary: Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. The susceptibility of the reassortant viruses between H1 and H3 subtype influenza A viruses to Stachyflin indicated that its target was virus-encoded hemagglutinin (HA). The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. More directly, Stachyflin interfered with HA conformational change induced by low pH or heat treatment. The effect of Stachyflin could not be eliminated by washing of the Stachyflin-treated virus, which caused very specific virucidal effect. This is a remarkable property among small molecules which inhibit low-pH induced HA conformational change. From these findings, we concluded that the mechanism of Stachyflin action is to inhibit HA conformational change which is necessary for virus-cell membrane fusion. Stachyflin may be used as a tool for a study of molecular mechanism of low-pH induced HA conformational change, and offers potential as a pharmaceutical agent.</abstract><qualityIndicators><score>9.148</score><pdfWordCount>5169</pdfWordCount><pdfCharCount>30406</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>14</pdfPageCount><pdfPageSize>595 x 786 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>179</abstractWordCount><abstractCharCount>1222</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Identification of a novel HA conformational change inhibitor of human influenza virus</title><genre><json:string>research-article</json:string></genre><host><title>Archives of Virology</title><language><json:string>unknown</json:string></language><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><issn><json:string>0304-8608</json:string></issn><eissn><json:string>1432-8798</json:string></eissn><journalId><json:string>705</json:string></journalId><volume>144</volume><issue>5</issue><pages><first>865</first><last>878</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Biomedicine</value></json:item><json:item><value>Virology</value></json:item><json:item><value>Medical Microbiology</value></json:item><json:item><value>Infectious Diseases</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-JW8BS4G7-Q</json:string></ark><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1007/s007050050552</json:string></doi><id>23B352D5518AF38A2976BC28D266B92B7C42B326</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-JW8BS4G7-Q/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-JW8BS4G7-Q/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-JW8BS4G7-Q/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Identification of a novel HA conformational change inhibitor of human influenza virus</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><availability><licence><p>Springer-Verlag, 1999</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>1999</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Identification of a novel HA conformational change inhibitor of human influenza virus</title><author xml:id="author-0000"><persName><forename type="first">J.</forename><surname>Yoshimoto</surname></persName><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation></author><author xml:id="author-0001"><persName><forename type="first">M.</forename><surname>Kakui</surname></persName><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation></author><author xml:id="author-0002"><persName><forename type="first">H.</forename><surname>Iwasaki</surname></persName><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation></author><author xml:id="author-0003"><persName><forename type="first">T.</forename><surname>Fujiwara</surname></persName><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation></author><author xml:id="author-0004"><persName><forename type="first">H.</forename><surname>Sugimoto</surname></persName><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation></author><author xml:id="author-0005"><persName><forename type="first">N.</forename><surname>Hattori</surname></persName><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation></author><idno type="istex">23B352D5518AF38A2976BC28D266B92B7C42B326</idno><idno type="ark">ark:/67375/VQC-JW8BS4G7-Q</idno><idno type="DOI">10.1007/s007050050552</idno><idno type="article-id">91440865</idno><idno type="article-id">Art2</idno></analytic><monogr><title level="j">Archives of Virology</title><title level="j" type="abbrev">Arch. Virol.</title><idno type="pISSN">0304-8608</idno><idno type="eISSN">1432-8798</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">18</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1999-05-01"></date><biblScope unit="volume">144</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="865">865</biblScope><biblScope unit="page" to="878">878</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. The susceptibility of the reassortant viruses between H1 and H3 subtype influenza A viruses to Stachyflin indicated that its target was virus-encoded hemagglutinin (HA). The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. More directly, Stachyflin interfered with HA conformational change induced by low pH or heat treatment. The effect of Stachyflin could not be eliminated by washing of the Stachyflin-treated virus, which caused very specific virucidal effect. This is a remarkable property among small molecules which inhibit low-pH induced HA conformational change. From these findings, we concluded that the mechanism of Stachyflin action is to inhibit HA conformational change which is necessary for virus-cell membrane fusion. Stachyflin may be used as a tool for a study of molecular mechanism of low-pH induced HA conformational change, and offers potential as a pharmaceutical agent.</p></abstract><textClass><keywords scheme="Journal-Subject-Group"><list><label>SCB</label><item><term>Biomedicine</term></item><label>SCB22003</label><item><term>Virology</term></item><label>SCB16003</label><item><term>Medical Microbiology</term></item><label>SCH33096</label><item><term>Infectious Diseases</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-05-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-JW8BS4G7-Q/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Vienna</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>705</JournalID><JournalPrintISSN>0304-8608</JournalPrintISSN><JournalElectronicISSN>1432-8798</JournalElectronicISSN><JournalTitle>Archives of Virology</JournalTitle><JournalAbbreviatedTitle>Arch. Virol.</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Code="SCB" Type="Primary">Biomedicine</JournalSubject><JournalSubject Code="SCB22003" Priority="1" Type="Secondary">Virology</JournalSubject><JournalSubject Code="SCB16003" Priority="2" Type="Secondary">Medical Microbiology</JournalSubject><JournalSubject Code="SCH33096" Priority="3" Type="Secondary">Infectious Diseases</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>144</VolumeIDStart><VolumeIDEnd>144</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>5</IssueIDStart><IssueIDEnd>5</IssueIDEnd><IssueArticleCount>18</IssueArticleCount><IssueHistory><CoverDate><Year>1999</Year><Month>5</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1999</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art2"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>91440865</ArticleID><ArticleDOI>10.1007/s007050050552</ArticleDOI><ArticleSequenceNumber>2</ArticleSequenceNumber><ArticleTitle Language="En">Identification of a novel HA conformational change inhibitor of human influenza virus</ArticleTitle><ArticleFirstPage>865</ArticleFirstPage><ArticleLastPage>878</ArticleLastPage><ArticleHistory><RegistrationDate><Year>1999</Year><Month>5</Month><Day>18</Day></RegistrationDate><OnlineDate><Year>2014</Year><Month>5</Month><Day>18</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1999</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>J.</GivenName><FamilyName>Yoshimoto</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Kakui</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><FamilyName>Iwasaki</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>T.</GivenName><FamilyName>Fujiwara</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><FamilyName>Sugimoto</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>N.</GivenName><FamilyName>Hattori</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgName>Shionogi Discovery Research Laboratories, Osaka, Japan</OrgName><OrgAddress><Country>Japan</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. The susceptibility of the reassortant viruses between H1 and H3 subtype influenza A viruses to Stachyflin indicated that its target was virus-encoded hemagglutinin (HA). The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. More directly, Stachyflin interfered with HA conformational change induced by low pH or heat treatment. The effect of Stachyflin could not be eliminated by washing of the Stachyflin-treated virus, which caused very specific virucidal effect. This is a remarkable property among small molecules which inhibit low-pH induced HA conformational change. From these findings, we concluded that the mechanism of Stachyflin action is to inhibit HA conformational change which is necessary for virus-cell membrane fusion. Stachyflin may be used as a tool for a study of molecular mechanism of low-pH induced HA conformational change, and offers potential as a pharmaceutical agent.</Para></Abstract><ArticleNote Type="Misc"><SimplePara>Received November 25, 1998 Accepted January 21, 1999</SimplePara></ArticleNote></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Identification of a novel HA conformational change inhibitor of human influenza virus</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Identification of a novel HA conformational change inhibitor of human influenza virus</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Yoshimoto</namePart><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Kakui</namePart><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Iwasaki</namePart><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Fujiwara</namePart><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Sugimoto</namePart><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Hattori</namePart><affiliation>Shionogi Discovery Research Laboratories, Osaka, Japan, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Vienna</placeTerm></place><dateIssued encoding="w3cdtf">1999-05-01</dateIssued><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Summary: Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. The susceptibility of the reassortant viruses between H1 and H3 subtype influenza A viruses to Stachyflin indicated that its target was virus-encoded hemagglutinin (HA). The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. More directly, Stachyflin interfered with HA conformational change induced by low pH or heat treatment. The effect of Stachyflin could not be eliminated by washing of the Stachyflin-treated virus, which caused very specific virucidal effect. This is a remarkable property among small molecules which inhibit low-pH induced HA conformational change. From these findings, we concluded that the mechanism of Stachyflin action is to inhibit HA conformational change which is necessary for virus-cell membrane fusion. Stachyflin may be used as a tool for a study of molecular mechanism of low-pH induced HA conformational change, and offers potential as a pharmaceutical agent.</abstract><relatedItem type="host"><titleInfo><title>Archives of Virology</title></titleInfo><titleInfo type="abbreviated"><title>Arch. Virol.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">1999-05-01</dateIssued><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><subject><genre>Journal-Subject-Group</genre><topic authority="SpringerSubjectCodes" authorityURI="SCB">Biomedicine</topic><topic authority="SpringerSubjectCodes" authorityURI="SCB22003">Virology</topic><topic authority="SpringerSubjectCodes" authorityURI="SCB16003">Medical Microbiology</topic><topic authority="SpringerSubjectCodes" authorityURI="SCH33096">Infectious Diseases</topic></subject><identifier type="ISSN">0304-8608</identifier><identifier type="eISSN">1432-8798</identifier><identifier type="JournalID">705</identifier><identifier type="IssueArticleCount">18</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>1999</date><detail type="volume"><number>144</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="pages"><start>865</start><end>878</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1999</recordOrigin></recordInfo></relatedItem><identifier type="istex">23B352D5518AF38A2976BC28D266B92B7C42B326</identifier><identifier type="ark">ark:/67375/VQC-JW8BS4G7-Q</identifier><identifier type="DOI">10.1007/s007050050552</identifier><identifier type="ArticleID">91440865</identifier><identifier type="ArticleID">Art2</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag, 1999</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Springer-Verlag, 1999</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-JW8BS4G7-Q/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000249 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000249 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:23B352D5518AF38A2976BC28D266B92B7C42B326
|texte= Identification of a novel HA conformational change inhibitor of human influenza virus
}}
| This area was generated with Dilib version V0.6.33. |  |